Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial

Trial Profile

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Myocardial infarction; Stroke; Transient ischaemic attacks
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POINT
  • Most Recent Events

    • 04 Jan 2024 Results of post hoc secondary analysis determining how baseline stroke risk modified the efficacy of clopidogrel-aspirin for transient ischemic attack and minor ischemic stroke, published in the Stroke
    • 26 Apr 2022 Results identifying predictors of very early stroke recurrence, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 11 Feb 2022 Results of post-hoc analysis assessing effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and determine whether smoking improves the effect of clopidogrel treatment on subsequent stroke risk reduction presented at the International Stroke Conference 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top